The application of molecular topology for ulcerative colitis drug discovery

References

• Ordás I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet. 2012;380:1606–1619.
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN. Environmental risk factors for inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2013;9:367–374.
   PubMedGoogle Scholar
• Molodecky NA, Kaplan GG. Environmental risk factors for inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2010;6:339–346.
   PubMedGoogle Scholar
• De Souza HSP. Etiopathogenesis of inflammatory bowel disease: today and tomorrow. Curr Opin Gastroenterol. 2017;33:222–229.
   PubMed Web of Science ®Google Scholar
• Cleynen I, Boucher G, Jostins L, et al. Inherited determinants of Crohn’s disease and ulcerative colitis phenotypes: a genetic association study. Lancet. 2016;387:156–167.
   PubMed Web of Science ®Google Scholar
• Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365:1713–1725.
   PubMed Web of Science ®Google Scholar
• Hindryckx P, Jairath V, D’ Haens G. Acute severe ulcerative colitis: from pathophysiology to clinical management. Nat Rev Gastroenterol Hepatol. 2016;13:654–664.
   PubMed Web of Science ®Google Scholar
• Fuss I, Strober W. Ulcerative colitis. In: Mucosal immunology. 4th ed.Boston (MA): Academic Press; 2015.
   Google Scholar
• Pastorelli L, Pizarro TT, Cominelli F, et al. Emerging drugs for the treatment of ulcerative colitis. Expert Opin Emerging Drugs. 2009;14:505–521.
   PubMed Web of Science ®Google Scholar
• Dubinsky MC. Reviewing treatments and outcomes in the evolving landscape of ulcerative colitis. Postgrad Med. 2017;129:538–553.
   PubMed Web of Science ®Google Scholar
• Caprilli R, Cesarini M, Angelucci E, et al. The long journey of salicylates in ulcerative colitis: the past and the future. J Crohns Colitis. 2009;3:149–156.
   PubMed Web of Science ®Google Scholar
• Rosseaux C, Lefebvre L, Dubuquoy L, et al. Intestinal anti-inflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med. 2005;201:1205–1215.
   PubMed Web of Science ®Google Scholar
• Dubuquoy L, Rosseaux C, Thueru X, et al. PPARγ as a new therapeutic target in inflammatory bowel diseases. Gut. 2006;55:1341–1349.
   PubMed Web of Science ®Google Scholar
• Jannin V, Lemagnen G, Gueroult P, et al. Rectal route in the 21st Century to treat children. Adv Drug Deliv Rev. 2014;73:34–49.
   PubMed Web of Science ®Google Scholar
• Kornbluth A, Sachar DB; Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501–523.
   PubMed Web of Science ®Google Scholar
• Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255–260.
   PubMed Web of Science ®Google Scholar
• Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929–936.
   PubMed Web of Science ®Google Scholar
• Park SC, Jeen YT. Current and emerging biologics for ulcerative colitis. Gut Liver. 2015;9:18–27.
   PubMed Web of Science ®Google Scholar
• Petkau JMV, Eksteen B. Selective biologics for ulcerative colitis and Crohn’s disease - clinical utility of vedolizumab. Biologics. 2016;10:33–52.
   PubMedGoogle Scholar
• Stawowczyk E, Kawalec P. Cost-effectiveness of biological treatment of ulcerative colitis – a systematic review. Prz Gastroenterol. 2017;12:90–97.
   PubMed Web of Science ®Google Scholar
• Khanna R, Jairath V, Vande Casteele N, et al. Efficient early drug development for ulcerative colitis. Gastroenterology. 2016;150:1056–1060.
   PubMed Web of Science ®Google Scholar
• Gálvez J, Gálvez Llompart M, García-Domenech R. Molecular topology as a novel approach for drug discovery. Expert Opin Drug Discov. 2012;7:133–153.
   PubMed Web of Science ®Google Scholar
• Amigó JM, Gálvez J, Villar VM. A review on molecular topology: applying graph theory to drug discovery and design. Naturwissenschaften. 2009;96:749–761.
   PubMed Web of Science ®Google Scholar
• Gálvez J, García-Domenech R. On the contribution of molecular topology to drug design and discovery. Curr Comput Aided Drug Des. 2010;6:252–268.
   PubMed Web of Science ®Google Scholar
• Wang T, Wu M-B, Lin J-P, et al. Quantitative structure–activity relationship: promising advances in drug discovery platforms. Expert Opin Drug Discov. 2015;10:1283–1300.
   PubMed Web of Science ®Google Scholar
• Cherkasov A, Muratov EN, Fourches D, et al. QSAR modeling: where have you been? Where are you going to? J Med Chem. 2014;75:4977–5010.
   Google Scholar
• García-Domenech R, Gálvez-Llompart M, Zanni R, et al. QSAR methods for the discovery of new inflammatory bowel disease drugs. Expert Opin Drug Discov. 2013;8:933–949.
   PubMed Web of Science ®Google Scholar
• Gálvez-Llompart M, Recio MC, García-Domenech R. Topological virtual screening: A way to find new compounds active in ulcerative colitis by inhibiting NF-κB. Mol Divers. 2011;15:917–926.
   PubMed Web of Science ®Google Scholar
• Gálvez-Llompart M, Recio Iglesias MC, Gálvez J, et al. Novel potential agents for ulcerative colitis by molecular topology: suppression of IL-6 production in Caco-2 and RAW264.7 cell lines. Mol Divers. 2013;17:573–593.
   PubMed Web of Science ®Google Scholar
• Gálvez-Llompart M, Recio MC, García-Domenech R, et al. Molecular topology: A strategy to identify novel compounds against ulcerative colitis. Mol Divers. 2017;21:219–234.
   PubMed Web of Science ®Google Scholar
• Mayr LM, Bojanic D. Novel trends in high-throughput screening. Curr Opin Pharmacol. 2009;9:580–588.
   PubMed Web of Science ®Google Scholar
• Martins EA, Radhakrishan R, Badve RR. High-throughput screening: the hits and leads of drug discovery – an overview. J Appl Pharm Sci. 2011;1:2–10.
   Google Scholar
• Fang Y, Ding Y, Feinstein WP, et al. GeuxDock: accelerating structure-based virtual screening with heterogeneous computing. PLoS One. 2016;11:e0158898.
   PubMed Web of Science ®Google Scholar
• Ge H, Wang Y, Li C, et al. Molecular dynamics-based virtual screening: accelerating the drug discovery process by high-performance computing. J Chem Inf Model. 2013;53:2757–2764.
   PubMed Web of Science ®Google Scholar
• Kristensen TG, Nielsen J, Pedersen CNS. Methods for similarity-based virtual screening. Comput Struct Biotechnol J. 2013;5:e201302009.
   PubMedGoogle Scholar
• Cereto-Messagué A, Ojeda MJ, Valls C, et al. Molecular fingerprint similarity search in virtual screening. Methods. 2015;71:58–63.
   PubMed Web of Science ®Google Scholar
• Brown N, Lewis RA. Exploiting QSAR methods in lead optimization. Curr Opin Drug Discov Devel. 2006;9:419–424.
   PubMed Web of Science ®Google Scholar
• Miyao T, Kaneko H, Funatsu K. Inverse QSPR/QSAR analysis for chemical structure generation (from y to x). J Chem Inf Model. 2016;56:286–299.
   PubMed Web of Science ®Google Scholar
• McGaughey G, Sheridan R, Bayly C, et al. Comparison of topological, shape, and docking methods in virtual screening. J Chem Inf Model. 2007;47(4):1504–1519.
   PubMed Web of Science ®Google Scholar
• Talevi A, Bellera C, Castro E, et al. A successful virtual screening application: prediction of anticonvulsant activity in MES test of widely used pharmaceutical and food preservatives methylparaben and propylparaben. J Comput Aid Mol Des. 2007;21(9):527–538.
   PubMed Web of Science ®Google Scholar
• Lara-Valderrábano L, Rocha L, Galván E. Propylparaben reduces the excitability of hippocampal neurons by blocking sodium channels. NeuroToxicol. 2016;57:183–193.
   PubMed Web of Science ®Google Scholar
• Lara-Valderrábano L, Galván E, Rocha L. Propylparaben suppresses epileptiform activity in hippocampal CA1 pyramidal cells in vitro. Epilepsy Res. 2017;136:126–129.
   PubMed Web of Science ®Google Scholar
• Santana-Gómez C, Orozco-Suárez S, Talevi A, et al. Propylparaben applied after pilocarpine-induced status epilepticus modifies hippocampal excitability and glutamate release in rats. NeuroToxicol. 2017;59:110–120.
   PubMed Web of Science ®Google Scholar
• Bellera C, Balcazar D, Vanrell M, et al. Computer-guided drug repurposing: identification of trypanocidal activity of clofazimine, benidipine and saquinavir. Eur J Med Chem. 2015;93:338–348.
   PubMed Web of Science ®Google Scholar
• Sbaraglini M, Bellera C, Fraccaroli L, et al. Novel cruzipain inhibitors for the chemotherapy of chronic Chagas disease. Int J Antimicrob Agents. 2016;48(1):91–95.
   PubMed Web of Science ®Google Scholar
• Chen H, Yang Y, Engkvist O. Molecular topology analysis of the differences between drugs, clinical candidate compounds, and bioactive molecules. J Chem Inf Model. 2010;50(12):2141–2150.
   PubMed Web of Science ®Google Scholar
• Contrera J, Matthews E, Kruhlak N, et al. Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose. Regul Toxicol Pharmacol. 2004;40(3):185–206.
   PubMed Web of Science ®Google Scholar
• Zanni R, Galvez-Llompart M, García-Domenech R, et al. Latest advances in molecular topology applications for drug discovery. Expert Opin Drug Discov. 2015;10:945–957.
   PubMed Web of Science ®Google Scholar
• Randic M. Characterization of molecular branching. J Am Chem Soc. 1975;97:6609–6615.
   Web of Science ®Google Scholar
• Wiener H. Structural determination of paraffin boiling points. J Am Chem Soc. 1947;69:17–20.
   PubMed Web of Science ®Google Scholar
• Talevi A, Bruno-Blanch LE. Virtual screening applications in the search of novel antiepileptic drug candidates. In: Talevi A, Rocha L. Antiepileptic drug discovery. New York (NY): Springer; 2016.
   Google Scholar
• Guimarāes MC, Duarte MH, Silla JM. Is conformation a fundamental descriptor in QSAR? A case for halogenated anesthesics. Beilstein J Org Chem. 2016;12:760–768.
   PubMed Web of Science ®Google Scholar
• Furtula B, Lekishvili G, Gutman I. A graph theoretical approach to cis/trans isomerism. J Serbian Chemi Soc. 2014;79:805–813.
   Web of Science ®Google Scholar
• Todeschini R, Consonni V. Handbook of molecular descriptors. Weinheim: Wiley-VCH; 2008.
   Google Scholar
• Hanser T, Barber C, Marchaland JF, et al. Applicability domain: towards a more formal definition. SAR QSAR Environ Res. 2016;27:893–909.
   PubMed Web of Science ®Google Scholar
• Ellison CM, Sherhod R, Cronin MT, et al. Assessment of methods to define the applicability domain of structural alert models. J Chem Inf Model. 2011;51:975–985.
   PubMed Web of Science ®Google Scholar
• Qin C, Zhang C, Xu F, et al. Theraeutic target database update 2014: A resource for targeted therapeutics. Nucleic Acids Res. 2014;42:D1118–D1123.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Su C, Sands BE. Tolfacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723–1736.
   PubMed Web of Science ®Google Scholar
• Danese S. New therapies for inflammatory bowel disease: from the bench to the bedside. Gut. 2012;61(6):918–932.
   PubMed Web of Science ®Google Scholar
• Cătană C, Neagoe I, Cozma V, et al. Contribution of the IL-17/IL-23 axis to the pathogenesis of inflammatory bowel disease. World J Gastroenterol. 2015;21(19):5823–5830.
   PubMed Web of Science ®Google Scholar
• Teng M, Bowman E, McElwee J, et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med. 2015;21(7):719–729.
   PubMed Web of Science ®Google Scholar
• Oeckinghaus A, Ghosh S. The NF-κB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol. 2009;1:a000034.
   PubMed Web of Science ®Google Scholar
• Lawrence T. The nuclear factor NF-κB pathway in inflammation. Cold Spring Harb Perspect Biol. 2009;1:a001651.
   PubMed Web of Science ®Google Scholar
• Langer T, Byrant SD. 3D quantitative structure-property relationships. In: Wermuth C. The practice of medicinal chemistry. London: Academic Press; 2008.
   Google Scholar
• Sippl W. 3D QSAR: applications, recent advances, and limitations. In: Puzyn T, Leszczynski J, Cronin MT. Recent advances in QSAR studies. Method and applications. Dordrecht: Springer; 2010.
   Google Scholar
• Roy K, Kar S, Das RN. Understanding the basics of QSAR for applications in pharmaceutical sciences and risk assessment. London (UK): Academic Press; 2015. Chapter 1, Background of QSAR and historical developments, p. 1-46.
   Google Scholar
• Alagarsamy V. Textbook in medicinal chemistry. Vol. 1. New Delhi (India): Elsevier; 2013. Chapter 4, Structure-activity relationship and quantitative structure-activity relationship, p. 56-65.
   Google Scholar
• Nikolic K, Agbaba D. QSAR study and design of novel organoselenium and α-tocopherol derivatives with enhanced chemotherapeutic activity. Lett Drug Des Discov. 2009;6:228–235.
   Web of Science ®Google Scholar
• Bello-Ramirez AM, Buendía-Orozco J, Nava-Ocampo AA. A QSAR analysis to explain the analgesic properties of aconitum alkaloids. Fundam Clin Pharmacol. 2003;17:575–580.
   PubMed Web of Science ®Google Scholar
• Patel SR, Gangwal R, Sangamwar AT, et al. Synthesis, biological evaluation and 3D-QSAR study of hydrazide, semicarbazide and thiosemicarbazide derivatives of 4-(adamantan-1-yl)quinoline as anti-tuberculosis agents. Eur J Med Chem. 2014;85:255–267.
   PubMed Web of Science ®Google Scholar
• Richard AM, Benigni R. AI and SAR approaches for predicting chemical carcinogenicity: survey and status report. SAR QSAR Environ Res. 2002;13:1–19.
   PubMed Web of Science ®Google Scholar
• Myshkin E, Brennan R, Khasanova T, et al. Prediction of organ toxicity endpoints by QSAR modeling based on precise chemical-histopathology annotations. Chem Biol Drug Des. 2012;80:406–416.
   PubMed Web of Science ®Google Scholar
• Tasso SM, Moon S, Bruno-Blanch LE, et al. Characterization of the anticonvulsant profile of valpromide derivatives. Bioorg Med Chem. 2004;12:3857–3869.
   PubMed Web of Science ®Google Scholar
• Shen M, LeTiran A, Xiao Y, et al. Quantitative structure−activity relationship analysis of functionalized amino acid anticonvulsant agents using k nearest neighbor and simulated annealing PLS methods. J Med Chem. 2002;45:2811–2823.
   PubMed Web of Science ®Google Scholar
• Talevi A, Enrique AV, Bruno-Blanch LE. Anticonvulsant activity of artificial sweeteners: a structural link between sweet-taste receptor T1R3 and brain glutamate receptors. Bioorg Med Chem Lett. 2012;22:4072–4074.
   PubMed Web of Science ®Google Scholar
• Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov. 2004;3:353–359.
   PubMed Web of Science ®Google Scholar
• Bianchi MT, Pathmanathan J, Cash SS. From ion channels to complex networks: magic bullet versus magic shotgun approaches to anticonvulsant pharmacotherapy. Med Hypotheses. 2009;72:297–305.
   PubMed Web of Science ®Google Scholar
• Talevi A. Multi-target pharmacology: possibilities and limitations of the “skeleton key approach” from a medicinal chemist perspective. Front Pharmacol. 2015;6:20564.
   Web of Science ®Google Scholar
• Sams-Dodd F. Target-based drug discovery: is something wrong? Drug Discov Today. 2005;10:139–147.
   PubMed Web of Science ®Google Scholar
• Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008;4:682–690.
   PubMed Web of Science ®Google Scholar
• Swinney DC, Anthony J. How were new medicines discovered? Nat Rev Drug Discov. 2011;10:507–519.
   PubMed Web of Science ®Google Scholar
• Muraro D, Simmons A. An integrative analysis of gene expression and molecular interaction data to identify dys-regulated sub-networks in inflammatory bowel disease. BMC Bioinformatics. 2016;17(1):art. no. 42.
   PubMedGoogle Scholar
• Emig D, Ivliev A, Pustovalova O, et al. Drug target prediction and repositioning using an integrated network-based approach. PLoS ONE. 2013;8(4):art. no. e60618.
   PubMed Web of Science ®Google Scholar
• De Julian Ortiz JV, Galvez J, Muñoz-Collado C, et al. Virtual combinatorial syntheses and computational screening of new potential anti-herpes compounds. J Med Chem. 1999;42:3308–3314.
   PubMed Web of Science ®Google Scholar
• Bruno-Blanch LE, Galvez J, García-Domenech R. Topological virtual screening: a way to find new anticonvulsant drugs from chemical diversity. Bioorg Med Chem Lett. 2003;13:2749–2754.
   PubMed Web of Science ®Google Scholar
• Rios-Santamarina I, García-Domenech R, Galvez J. New bronchodilators selected by molecular topology. Bioorg Med Chem Lett. 1998;8:477–482.
   PubMed Web of Science ®Google Scholar
• Galvez J, García-Domenech R, Gomez-Lechon M, et al. Use of molecular topology in the selection of new cytostatic drugs. J Mol Struct Theochem. 2000;504:241–248.
   Web of Science ®Google Scholar
• De Gregorio Alapont C, García-Domenech R, Galvez J, et al. Molecular topology: a useful tool for the search of new antibacterials. Bioorg Med Chem Lett. 2000;10:2033–2036.
   PubMed Web of Science ®Google Scholar
• García-Domenech R, Ríos-Santamarina I, Catalá A, et al. Application of molecular topology to the prediction of antifungal activity for a set of dication-substituted carbazols, furans and benzimidazoles. J Mol Struct Theochem. 2003;624:97–107.
   Web of Science ®Google Scholar
• Calabuig C, Antón-Fos GM, Galvez J, et al. New hypoglycaemic agents selected by molecular topology. Int J Pharm. 2004;278:111–118.
   PubMedGoogle Scholar
• Talevi A. Network pharmacology and epilepsy. In: Talevi A, Rocha L. Antiepileptic drug discovery. New York (NY): Springer; 2016.
   Google Scholar
• Marrero-Ponce Y, Ivarreta-Veitía M, Montero-Torres A, et al. Ligand-based virtual screening and in silico design of new antimalarial compounds using nonstochastic and stochastic total and atom-type quadratic maps. J Chem Inf Model. 2005;45:1082–1100.
   PubMed Web of Science ®Google Scholar
• Gavernet L, Talevi A, Castro E, et al. A combined virtual screening 2D and 3D QSAR methodology for the selection of new anticonvulsant candidates from a natural product library. QSAR Comb Sci. 2008;27(9):1120–1129.
   Google Scholar
• Speck-Panche A, Cordeiro MN. Multitasking models for quantitative structure-biological effect relationships: current status and future perspectives to speed up drug discovery. Expert Opin Drug Discov. 2015;10:245–256.
   PubMed Web of Science ®Google Scholar
• Cronin MTD. Quantitative structure-activity relationships (QSARs) – applications and methodology. In: Puzyn T, Leszczynski J, Cronin MT. Recent advances in QSAR studies. Method and applications. Dordrecht: Springer; 2010.
   Google Scholar
• Matsumoto S, Hara T, Hori T, et al. Probiotic Lactobacillus induced improvement in murine chronic inflammatory bowel disease is associated with the down-regulation of pro-inflammatory cytokines in lamina propia mononuclear cells. Clin Exp Immunol. 2005;140:417–426.
   PubMed Web of Science ®Google Scholar
• Waldner MJ, Neurath MF. Novel cytokine-targeted therapies and intestinal inflammation. Curr Opin Pharmacol. 2009;9:702–707.
   PubMed Web of Science ®Google Scholar
• Venkiteshwaran A. Tocilizumab. MAbs. 2009;1:432–438.
   PubMed Web of Science ®Google Scholar
• Szeto MCH, Yalcin MD, Khan A, et al. Successful use of tocilizumab in a patient with coexisting rheumatoid arthritis and ulcerative colitis. Case Report Immunol. 2016;2016:7562123.
   PubMedGoogle Scholar
• Atreya R, Billmeier U, Rath T, et al. First case reporto f exacerbated ulcerative colitis after anti-interleukin-6R salvage therapy. World J Gastroenterol. 2015;21:12963–12969.
   PubMed Web of Science ®Google Scholar
• Pourbasheer E, Riahi S, Ganiali MR, et al. Quantitative structure-activity relationship (QSAR) study of interleukin-1 receptor associated kinase 4 (IRAK-4) inhibitor activity by the genetic algorithm and multiple linear regression (GA-MLR) method. J Enzyme Inhib Med Chem. 2010;25:844–853.
   PubMed Web of Science ®Google Scholar
• Janssens S, Beyaert R. Functional diversity and regulation of different interleukin-1 receptor-associated kinase (IRAK) family members. Mol Cell. 2003;11:293–302.
   PubMed Web of Science ®Google Scholar
• Asadollahi T, Dadfarnia S, Shabani AMH, et al. QSAR models for CXCR2 receptor antagonists based on the genetic algorithm for data preprocessing prior to application of the PLS linear regression method and design of the new compounds using in silico virtual screening. Molecules. 2011;16:1928–1955.
   PubMed Web of Science ®Google Scholar
• Ghasemi JB, Zohrabi P, Khajehsharif H. Quantitative structure-activity relationship study of nonpeptide antagonists of CXCR2 using stepwise multiple linear regression analysis. Monatsch Chem. 2010;141:111–118.
   Web of Science ®Google Scholar
• Jain HK, Agrawal RK. Topological descriptors in modeling tumor necrosis factor alpha inhibitory activity of xanthines, pteridinediones and related compounds. Internet Electron J Mol Des. 2007;6:218–228.
   Google Scholar
• Zhang Y, Zhao L, Wu J, et al. Synthesis and evaluation of a series of novel asymmetrical curcumin analogs for the treatment of inflammation. Molecules. 2014;19:7287–7307.
   PubMedGoogle Scholar
• Jalali-Heravi M, Mani Varnosfaderani A. QSAR modelling of integrin antagonists using enhanced Bayesian regularised genetic neural networks. SAR QSAR Environ Res. 2011;22:293–314.
   PubMed Web of Science ®Google Scholar
• Pourbasheer E, Aalizadeh R, Ganjali MR, et al. QSAR study of α1β4 integrin inhibitors by GA-MLR and GA-SVM methods. Struct Chem. 2014;25:355–370.
   Web of Science ®Google Scholar
• Bhonde MR, Gupte RD, Dadarkar SD, et al. A novel mTOR inhibitor is efficacious in a murine model of colitis. Am J Physiol Gastrointest Liver Physiol. 2008;295:G1237–1245.
   PubMed Web of Science ®Google Scholar
• Hu S, Chen M, Wang Y. mTOR inhibition attenuates dextran sulfate sodium-induced colitis by suppressing T cell proliferation and balancing TH1/TmTOR inhibition attenuates dextran sulfate sodium-induced colitis by suppressing T cell proliferation and balancing TH1/TH17/Treg Profile. PLoS ONE. 2016;11:e0154564.
   PubMed Web of Science ®Google Scholar
• Lakhlili W, Yasri A, Ibrahimi A. Structure–activity relationships study of mTORkinase inhibition using QSAR and structure-based drug design approaches. Onco Targets Ther. 2016;9:7345–7353.
   PubMed Web of Science ®Google Scholar